First Berlin Reiterates Buy on Pharming Group With EUR 2.20 Price Target

• First Berlin Equity Research reiterated its Buy rating on Pharming Group in an Oct. 23, 2026, research update.
• Analyst Simon Scholes maintained a EUR 2.20 price target, implying 133% upside.
• Third-quarter Ruconest revenue rose 14% year over year to USD 93.8 million.
• Sales increased 30% sequentially, exceeding the consensus forecast of USD 81.7 million.
• Management reaffirmed the 2026 group revenue guidance midpoint of USD 385 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via EQS News (Ref. ID: rc_27168) on October 23, 2026, and is solely responsible for the information contained therein.